126 related articles for article (PubMed ID: 33161254)
1. Investigation of serum and brain superoxide dismutase levels depending on atomoxetine used in attention-deficit/hyperactivity disorder treatment: A combination of in vivo and molecular docking studies.
Gür F; Gür B; Erkayman B; Halıcı Z; Karakoç A
Bioorg Chem; 2020 Dec; 105():104435. PubMed ID: 33161254
[TBL] [Abstract][Full Text] [Related]
2. Alternations in nuclear factor kappa beta activity (NF-kB) in the rat brain due to long-term use of atomoxetine for treating ADHD: In vivo and in silico studies.
Gür F; Cengiz M; Gür B
Biochem Biophys Res Commun; 2021 Jan; 534():927-932. PubMed ID: 33143874
[TBL] [Abstract][Full Text] [Related]
3. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
4. Different effects of methylphenidate and atomoxetine on the behavior and brain transcriptome of zebrafish.
Suzuki S; Kimura R; Maegawa S; Nakata M; Hagiwara M
Mol Brain; 2020 May; 13(1):70. PubMed ID: 32375837
[TBL] [Abstract][Full Text] [Related]
5. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
Piña R; Rozas C; Contreras D; Hardy P; Ugarte G; Zeise ML; Rojas P; Morales B
Neuroscience; 2020 Jul; 439():268-274. PubMed ID: 31809728
[TBL] [Abstract][Full Text] [Related]
9. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
[TBL] [Abstract][Full Text] [Related]
10. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
11. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
Walker DJ; Mason O; Clemow DB; Day KA
Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
[TBL] [Abstract][Full Text] [Related]
14. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
Liu Q; Zhang H; Fang Q; Qin L
J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of atomoxetine and its metabolites in plasma and oral fluid from paediatric patients with attention deficit/hyperactivity disorder.
Papaseit E; Marchei E; Farré M; Garcia-Algar O; Pacifici R; Pichini S
Drug Test Anal; 2013 Jun; 5(6):446-52. PubMed ID: 22589233
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
[TBL] [Abstract][Full Text] [Related]
19. Differential long-term medication impact on executive function and delay aversion in ADHD.
Rubio Morell B; Hernández Expósito S
Appl Neuropsychol Child; 2019; 8(2):140-157. PubMed ID: 29244542
[TBL] [Abstract][Full Text] [Related]
20. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
